Sept 21 (Reuters) – Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes,
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
NOVO NORDISK US HEAD: 50% OF ENTIRE WEGOVY FRANCHISE AND 90% OF WEGOVY PILL US…
VIDEO SHOWS: FILE FOOTAGE OF SWITZERLAND MIDFIELDER GRANIT XHAKA SHOWS: VANCOUVER, CANADA (JULY 5, 2026)…
NOVO NORDISK US HEAD: NOVO HAS GAINED ROUGHLY 8 SHARE POINTS IN OBESITY SINCE JANUARY…
By Susan Heavey WASHINGTON, Sept 21 (Reuters) - MS NOW, CNN and Politico said on…
By Greg Bensinger and Deepa Seetharaman SAN FRANCISCO, Sept 19 (Reuters) - For years, the…
Sept 21 (Reuters) - Dri Healthcare Trust: * DRI HEALTHCARE ANNOUNCES US$316 MILLION PURCHASE OF…